| Project/Area Number |
63480279
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Jichi Medical School |
|---|
Principal Investigator |
MOTOYOSHI Kazuo Jichi Med. Sch. Dept. of Med. Assoc. Prof., 医学部, 助教授 (80137702)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAITO Masaki Jichi Med. Sch. Dept. of Med. Prof., 医学部, 教授 (60012762)
|
|---|
| Project Period (FY) |
1988 – 1989
|
| Project Status |
Completed (Fiscal Year 1989)
|
| Budget Amount *help |
¥6,300,000 (Direct Cost: ¥6,300,000)
Fiscal Year 1989: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 1988: ¥5,100,000 (Direct Cost: ¥5,100,000)
|
|---|
| Keywords | M-CSF / Granulocytopenia / Thrombocytopenia / Bone Marrow Transplantation / Survival rate / Megakaryocyte-potentiator / Tumor-killing activity / Myelodysplastic syndrome / MーCSF / 抗体依存性殺腫瘍活性 / 抗体非依存性殺腫瘍活性 / Fc受容体 / 腫瘍壊死因子 / 無顆粒球症 / 血中コレステロ-ル / 単球活性化 / Chromium Release Assay |
|---|
| Research Abstract |
Following results were obtained in this research project.
1) When human macrophage colony-stimulating factor (hM-CSF) was administered after anticancer chemotherapy, it accelerated both granulocyte and platelet recovery in patients with gynecologic malignancy and granulocyte recovery in patients with hematological malignancy.
2) Human M-CSF accelerated the granulocyte recovery and increased the survival rate of patients within 4 months after bone marrow transplantation. Human M-CSF did not increase the rate of leukemic relapse at 12-27 months after bone marrow transplantation.
3) Human M-CSF activated human monocutes to produce megakaryocyte- potentiating factor (Meg-POT) in vitro.
4) Human M-CSF enhanced antibody-dependent tumor-killing activity of human monocutes to Raji cells (Burkitt lymphoma-derived cell line).
5) Human M-CSF enhanced antibody-independent tumor-killing activity of human monocutes to several human leukemic cell lines such as K562, HL60, U937 and Daudi.
6) Changes in serum human M-CSF levels were monitored during neutropenic period after anticancer chemotherapy using enzyme-linked immunosorbent assay (ELISA). Negative correlation was found between the serum M-CSF level during neutropenic period and the duration of neutropenia.
7) Injection of human M-CSF resulted in the reduction of serum total cholesterol level in human and rabbits.
|
